Vectors (Development)

Optimized Retroviral Vectors Confer High-Dose Multidrug Resistance

Published in Gene Therapy Weekly, November 18th, 1996

Novel retroviral vectors achieve potent gene expression in early hematopoietic cells.

Preliminary gene therapy trials have emphasized the need for careful development and extensive preclinical testing of basic gene transfer technologies. Each gene therapy approach requires optimization of transduction protocols and vector design in order to reduce potential risks and increase efficiency.

German researchers Hans-Georg Eckert et al. have focused on improving retroviral vector design in order to obtain high and stable gene expression levels in early hematopoietic cells and their progeny ("High-Dose Multidrug Resistance in Primary Human Hematopoietic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1996-11-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry